4//SEC Filing
Hopman Mark 4
Accession 0001415889-25-022540
CIK 0001674632other
Filed
Aug 19, 8:00 PM ET
Accepted
Aug 20, 9:30 PM ET
Size
9.0 KB
Accession
0001415889-25-022540
Insider Transaction Report
Form 4
Hopman Mark
Chief Commercial Officer
Transactions
- Exercise/Conversion
Employee Stock Option (right to buy)
2025-08-19−16,158→ 67,084 totalExercise: $5.10Exp: 2033-07-26→ Common Stock (16,158 underlying) - Exercise/Conversion
Common Stock
2025-08-19$5.10/sh+16,158$82,406→ 50,290 total - Sale
Common Stock
2025-08-19$16.61/sh−16,158$268,376→ 34,132 total
Footnotes (3)
- [F1]Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025.
- [F2]The weighted average sale price for the transaction reported was $16.6095 and the range of prices were between $16.26 and $17.1719. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]One-fourth of the shares subject to this option shall vest one year after March 20, 2023, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof.
Documents
Issuer
Beta Bionics, Inc.
CIK 0001674632
Entity typeother
Related Parties
1- filerCIK 0002048497
Filing Metadata
- Form type
- 4
- Filed
- Aug 19, 8:00 PM ET
- Accepted
- Aug 20, 9:30 PM ET
- Size
- 9.0 KB